Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Opioid-Induced Constipation market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Opioid-Induced Constipation market. Detailed analysis of key players, along with key growth strategies adopted by Opioid-Induced Constipation industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Prestige
Purdue Pharm
Sanofi
GSK
Salix (Bausch Health)
Nektar Therapeutics
Daiichi Sankyo
Bayer
AstraZeneca
Takeda Pharmaceuticals
Mallinckrodt
Shionogi
Progenics Pharmaceuticals
By Type:
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
By End-User:
Hospital
Pharmacy
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Opioid-Induced Constipation Market
-
1.3 Market Segment by Type
-
1.3.1 USA Opioid-Induced Constipation Market Size and Growth Rate of Methylnaltrexone Bromide from 2016 to 2027
-
1.3.2 USA Opioid-Induced Constipation Market Size and Growth Rate of Lubiprostone from 2016 to 2027
-
1.3.3 USA Opioid-Induced Constipation Market Size and Growth Rate of Naloxegol from 2016 to 2027
-
1.3.4 USA Opioid-Induced Constipation Market Size and Growth Rate of Others from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Opioid-Induced Constipation Market Size and Growth Rate of Hospital from 2016 to 2027
-
1.4.2 USA Opioid-Induced Constipation Market Size and Growth Rate of Pharmacy from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Opioid-Induced Constipation Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Opioid-Induced Constipation by Major Types
-
3.4.1 Market Size and Growth Rate of Methylnaltrexone Bromide
-
3.4.2 Market Size and Growth Rate of Lubiprostone
-
3.4.3 Market Size and Growth Rate of Naloxegol
-
3.4.4 Market Size and Growth Rate of Others
4 Segmentation of Opioid-Induced Constipation Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Opioid-Induced Constipation by Major End-Users
-
4.4.1 Market Size and Growth Rate of Opioid-Induced Constipation in Hospital
-
4.4.2 Market Size and Growth Rate of Opioid-Induced Constipation in Pharmacy
5 Market Analysis by Regions
-
5.1 USA Opioid-Induced Constipation Production Analysis by Regions
-
5.2 USA Opioid-Induced Constipation Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Opioid-Induced Constipation Landscape Analysis
-
6.1 West USA Opioid-Induced Constipation Landscape Analysis by Major Types
-
6.2 West USA Opioid-Induced Constipation Landscape Analysis by Major End-Users
7 South USA Opioid-Induced Constipation Landscape Analysis
-
7.1 South USA Opioid-Induced Constipation Landscape Analysis by Major Types
-
7.2 South USA Opioid-Induced Constipation Landscape Analysis by Major End-Users
8 Middle West USA Opioid-Induced Constipation Landscape Analysis
-
8.1 Middle West USA Opioid-Induced Constipation Landscape Analysis by Major Types
-
8.2 Middle West USA Opioid-Induced Constipation Landscape Analysis by Major End-Users
9 Northeast USA Opioid-Induced Constipation Landscape Analysis
-
9.1 Northeast USA Opioid-Induced Constipation Landscape Analysis by Major Types
-
9.2 Northeast USA Opioid-Induced Constipation Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Prestige
-
10.1.1 Prestige Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Purdue Pharm
-
10.2.1 Purdue Pharm Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 Sanofi
-
10.3.1 Sanofi Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 GSK
-
10.4.1 GSK Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Salix (Bausch Health)
-
10.5.1 Salix (Bausch Health) Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
-
10.6 Nektar Therapeutics
-
10.6.1 Nektar Therapeutics Company Profile and Recent Development
-
10.6.2 Market Performance
-
10.6.3 Product and Service Introduction
-
10.7 Daiichi Sankyo
-
10.7.1 Daiichi Sankyo Company Profile and Recent Development
-
10.7.2 Market Performance
-
10.7.3 Product and Service Introduction
-
10.8 Bayer
-
10.8.1 Bayer Company Profile and Recent Development
-
10.8.2 Market Performance
-
10.8.3 Product and Service Introduction
-
10.9 AstraZeneca
-
10.9.1 AstraZeneca Company Profile and Recent Development
-
10.9.2 Market Performance
-
10.9.3 Product and Service Introduction
-
10.10 Takeda Pharmaceuticals
-
10.10.1 Takeda Pharmaceuticals Company Profile and Recent Development
-
10.10.2 Market Performance
-
10.10.3 Product and Service Introduction
-
10.11 Mallinckrodt
-
10.11.1 Mallinckrodt Company Profile and Recent Development
-
10.11.2 Market Performance
-
10.11.3 Product and Service Introduction
-
10.12 Shionogi
-
10.12.1 Shionogi Company Profile and Recent Development
-
10.12.2 Market Performance
-
10.12.3 Product and Service Introduction
-
10.13 Progenics Pharmaceuticals
-
10.13.1 Progenics Pharmaceuticals Company Profile and Recent Development
-
10.13.2 Market Performance
-
10.13.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Methylnaltrexone Bromide from 2016 to 2027
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Lubiprostone from 2016 to 2027
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Naloxegol from 2016 to 2027
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Hospital from 2016 to 2027
-
Figure USA Opioid-Induced Constipation Market Size and Growth Rate of Pharmacy from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Opioid-Induced Constipation Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Opioid-Induced Constipation Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Opioid-Induced Constipation
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Opioid-Induced Constipation by Different Types from 2016 to 2027
-
Table Consumption Share of Opioid-Induced Constipation by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Methylnaltrexone Bromide
-
Figure Market Size and Growth Rate of Lubiprostone
-
Figure Market Size and Growth Rate of Naloxegol
-
Figure Market Size and Growth Rate of Others
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Opioid-Induced Constipation by Different End-Users from 2016 to 2027
-
Table Consumption Share of Opioid-Induced Constipation by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospital
-
Figure Market Size and Growth Rate of Pharmacy
-
Table USA Opioid-Induced Constipation Production by Regions
-
Table USA Opioid-Induced Constipation Production Share by Regions
-
Figure USA Opioid-Induced Constipation Production Share by Regions in 2016
-
Figure USA Opioid-Induced Constipation Production Share by Regions in 2021
-
Figure USA Opioid-Induced Constipation Production Share by Regions in 2027
-
Table USA Opioid-Induced Constipation Consumption by Regions
-
Table USA Opioid-Induced Constipation Consumption Share by Regions
-
Figure USA Opioid-Induced Constipation Consumption Share by Regions in 2016
-
Figure USA Opioid-Induced Constipation Consumption Share by Regions in 2021
-
Figure USA Opioid-Induced Constipation Consumption Share by Regions in 2027
-
Table West USA Opioid-Induced Constipation Consumption by Types from 2016 to 2027
-
Table West USA Opioid-Induced Constipation Consumption Share by Types from 2016 to 2027
-
Figure West USA Opioid-Induced Constipation Consumption Share by Types in 2016
-
Figure West USA Opioid-Induced Constipation Consumption Share by Types in 2021
-
Figure West USA Opioid-Induced Constipation Consumption Share by Types in 2027
-
Table West USA Opioid-Induced Constipation Consumption by End-Users from 2016 to 2027
-
Table West USA Opioid-Induced Constipation Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Opioid-Induced Constipation Consumption Share by End-Users in 2016
-
Figure West USA Opioid-Induced Constipation Consumption Share by End-Users in 2021
-
Figure West USA Opioid-Induced Constipation Consumption Share by End-Users in 2027
-
Table South USA Opioid-Induced Constipation Consumption by Types from 2016 to 2027
-
Table South USA Opioid-Induced Constipation Consumption Share by Types from 2016 to 2027
-
Figure South USA Opioid-Induced Constipation Consumption Share by Types in 2016
-
Figure South USA Opioid-Induced Constipation Consumption Share by Types in 2021
-
Figure South USA Opioid-Induced Constipation Consumption Share by Types in 2027
-
Table South USA Opioid-Induced Constipation Consumption by End-Users from 2016 to 2027
-
Table South USA Opioid-Induced Constipation Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Opioid-Induced Constipation Consumption Share by End-Users in 2016
-
Figure South USA Opioid-Induced Constipation Consumption Share by End-Users in 2021
-
Figure South USA Opioid-Induced Constipation Consumption Share by End-Users in 2027
-
Table Middle West USA Opioid-Induced Constipation Consumption by Types from 2016 to 2027
-
Table Middle West USA Opioid-Induced Constipation Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by Types in 2016
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by Types in 2021
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by Types in 2027
-
Table Middle West USA Opioid-Induced Constipation Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Opioid-Induced Constipation Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by End-Users in 2016
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by End-Users in 2021
-
Figure Middle West USA Opioid-Induced Constipation Consumption Share by End-Users in 2027
-
Table Northeast USA Opioid-Induced Constipation Consumption by Types from 2016 to 2027
-
Table Northeast USA Opioid-Induced Constipation Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by Types in 2016
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by Types in 2021
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by Types in 2027
-
Table Northeast USA Opioid-Induced Constipation Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Opioid-Induced Constipation Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by End-Users in 2016
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by End-Users in 2021
-
Figure Northeast USA Opioid-Induced Constipation Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Prestige
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Prestige
-
Figure Sales and Growth Rate Analysis of Prestige
-
Figure Revenue and Market Share Analysis of Prestige
-
Table Product and Service Introduction of Prestige
-
Table Company Profile and Development Status of Purdue Pharm
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Purdue Pharm
-
Figure Sales and Growth Rate Analysis of Purdue Pharm
-
Figure Revenue and Market Share Analysis of Purdue Pharm
-
Table Product and Service Introduction of Purdue Pharm
-
Table Company Profile and Development Status of Sanofi
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi
-
Figure Sales and Growth Rate Analysis of Sanofi
-
Figure Revenue and Market Share Analysis of Sanofi
-
Table Product and Service Introduction of Sanofi
-
Table Company Profile and Development Status of GSK
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of GSK
-
Figure Sales and Growth Rate Analysis of GSK
-
Figure Revenue and Market Share Analysis of GSK
-
Table Product and Service Introduction of GSK
-
Table Company Profile and Development Status of Salix (Bausch Health)
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Salix (Bausch Health)
-
Figure Sales and Growth Rate Analysis of Salix (Bausch Health)
-
Figure Revenue and Market Share Analysis of Salix (Bausch Health)
-
Table Product and Service Introduction of Salix (Bausch Health)
-
Table Company Profile and Development Status of Nektar Therapeutics
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nektar Therapeutics
-
Figure Sales and Growth Rate Analysis of Nektar Therapeutics
-
Figure Revenue and Market Share Analysis of Nektar Therapeutics
-
Table Product and Service Introduction of Nektar Therapeutics
-
Table Company Profile and Development Status of Daiichi Sankyo
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daiichi Sankyo
-
Figure Sales and Growth Rate Analysis of Daiichi Sankyo
-
Figure Revenue and Market Share Analysis of Daiichi Sankyo
-
Table Product and Service Introduction of Daiichi Sankyo
-
Table Company Profile and Development Status of Bayer
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer
-
Figure Sales and Growth Rate Analysis of Bayer
-
Figure Revenue and Market Share Analysis of Bayer
-
Table Product and Service Introduction of Bayer
-
Table Company Profile and Development Status of AstraZeneca
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca
-
Figure Sales and Growth Rate Analysis of AstraZeneca
-
Figure Revenue and Market Share Analysis of AstraZeneca
-
Table Product and Service Introduction of AstraZeneca
-
Table Company Profile and Development Status of Takeda Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Takeda Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Takeda Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Takeda Pharmaceuticals
-
Table Product and Service Introduction of Takeda Pharmaceuticals
-
Table Company Profile and Development Status of Mallinckrodt
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mallinckrodt
-
Figure Sales and Growth Rate Analysis of Mallinckrodt
-
Figure Revenue and Market Share Analysis of Mallinckrodt
-
Table Product and Service Introduction of Mallinckrodt
-
Table Company Profile and Development Status of Shionogi
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi
-
Figure Sales and Growth Rate Analysis of Shionogi
-
Figure Revenue and Market Share Analysis of Shionogi
-
Table Product and Service Introduction of Shionogi
-
Table Company Profile and Development Status of Progenics Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Progenics Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Progenics Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Progenics Pharmaceuticals
-
Table Product and Service Introduction of Progenics Pharmaceuticals
-
